Literature DB >> 27480088

Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.

Tsai-Ling Liu1, Justin Trogdon2, Morris Weinberger3,4, Bruce Fried5, A Sidney Barritt6.   

Abstract

OBJECTIVES: Liver cirrhosis is a leading cause of morbidity and mortality in the USA. Diabetes is common and increasing in incidence. Patients with compensated cirrhosis and diabetes may be at greater risk of clinical decompensation. We examined the risk of decompensation among a large sample of working-aged insured patients dually diagnosed with compensated cirrhosis and diabetes.
METHODS: This retrospective study used MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases (2000-2013). Decompensation events included incident ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, acute renal failure, and hepatocellular carcinoma. Dually diagnosed patients were defined as patients with cirrhosis and diabetes using previously published ICD-9 coding strategies. Adjusted odds ratios (ORs), hazard ratios (HRs), and confidence intervals (CI) were estimated using logistic regression and Cox proportional hazard models.
RESULTS: Of 72,731 patients with compensated cirrhosis, 20,477 patients (28.15 %) were diagnosed with diabetes. After controlling for patient characteristics and medication usage, the odds of developing any decompensation event were 1.14 times higher for patients with cirrhosis and diabetes than for patients with cirrhosis only (95 % CI 1.08-1.21, P value <0.01). In the Cox proportional hazard model, patients who were dually diagnosed with diabetes had a 1.32 times higher HR (95 % CI 1.26-1.39, P value <0.01) after controlling for time-to-event.
CONCLUSIONS: Patients dually diagnosed with compensated cirrhosis and diabetes had a higher risk of having decompensation events. Careful management of diabetes in patients with liver disease may reduce the risk of clinical decompensation in this population.

Entities:  

Keywords:  Liver diseases; Multiple chronic conditions; Secondary data

Mesh:

Year:  2016        PMID: 27480088     DOI: 10.1007/s10620-016-4261-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data.

Authors:  Danielle A Southern; Hude Quan; William A Ghali
Journal:  Med Care       Date:  2004-04       Impact factor: 2.983

2.  Statin use and the risk of liver cancer: a population-based case–control study.

Authors:  Hui-Fen Chiu; Shu-Chen Ho; Chih-Cheng Chen; Chun-Yuh Yang
Journal:  Am J Gastroenterol       Date:  2010-12-14       Impact factor: 10.864

3.  Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis.

Authors:  Jean Michel Petit; Samia Hamza; Fabien Rollot; Vanessa Sigonney; Elodie Crevisy; Laurence Duvillard; Jean Jacques Raab; Jean Pierre Bronowicki; Brigitte Bernard-Chabert; Vincent Di Martino; Michel Doffoel; Helene Barraud; Carine Richou; Jean Louis Jouve; Patrick Hillon
Journal:  Acta Diabetol       Date:  2013-12-19       Impact factor: 4.280

Review 4.  Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.

Authors:  Puneeta Tandon; Juan G Abraldes; Annalisa Berzigotti; Juan Carlos Garcia-Pagan; Jaime Bosch
Journal:  J Hepatol       Date:  2010-05-21       Impact factor: 25.083

5.  Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients.

Authors:  Chun-Hsun Yang; Yi-Chun Chiu; Chih-Hung Chen; Chien-Hung Chen; Ming-Chao Tsai; Seng-Kee Chuah; Chih-Hsiung Lee; Tsung-Hui Hu; Chao-Hung Hung
Journal:  Kaohsiung J Med Sci       Date:  2014-07-22       Impact factor: 2.744

Review 6.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

7.  Statins, risk of diabetes, and implications on outcomes in the general population.

Authors:  Kang-Ling Wang; Chia-Jen Liu; Tze-Fan Chao; Chi-Ming Huang; Cheng-Hsueh Wu; Su-Jung Chen; Tzeng-Ji Chen; Shing-Jong Lin; Chern-En Chiang
Journal:  J Am Coll Cardiol       Date:  2012-08-08       Impact factor: 24.094

8.  Prognostic significance of diabetes in patients with cirrhosis.

Authors:  G Bianchi; G Marchesini; M Zoli; E Bugianesi; A Fabbri; E Pisi
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

Review 9.  Metformin and the risk of cancer: time-related biases in observational studies.

Authors:  Samy Suissa; Laurent Azoulay
Journal:  Diabetes Care       Date:  2012-12       Impact factor: 19.112

10.  Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.

Authors:  Ali A Mokdad; Alan D Lopez; Saied Shahraz; Rafael Lozano; Ali H Mokdad; Jeff Stanaway; Christopher J L Murray; Mohsen Naghavi
Journal:  BMC Med       Date:  2014-09-18       Impact factor: 8.775

View more
  14 in total

1.  Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis.

Authors:  A Sidney Barritt; Yue Jiang; Monica Schmidt; Paul H Hayashi; Ramon Bataller
Journal:  Dig Dis Sci       Date:  2019-01-23       Impact factor: 3.199

2.  Practical Issues in the Management of Overt Hepatic Encephalopathy.

Authors:  Ganesh Pantham; Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

Review 3.  Why Do Individuals with Cirrhosis Fall? A Mechanistic Model for Fall Assessment, Treatment, and Research.

Authors:  Susan L Murphy; Elliot B Tapper; Jennifer Blackwood; James K Richardson
Journal:  Dig Dis Sci       Date:  2018-10-16       Impact factor: 3.199

Review 4.  Hepatogenous Diabetes: A Primer.

Authors:  Preetam Nath; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2021-05-01

5.  A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.

Authors:  Ganesh Pantham; Anthony Post; Deepak Venkat; Douglas Einstadter; Kevin D Mullen
Journal:  Dig Dis Sci       Date:  2017-05-30       Impact factor: 3.199

6.  Prevalence and Patterns of Opioid Use Before and After Liver Transplantation.

Authors:  David C Cron; Monica A Tincopa; Jay S Lee; Akbar K Waljee; Ali Hammoud; Chad M Brummett; Jennifer F Waljee; Michael J Englesbe; Christopher J Sonnenday
Journal:  Transplantation       Date:  2021-01-01       Impact factor: 5.385

7.  Who Treats Patients with Diabetes and Compensated Cirrhosis.

Authors:  Tsai-Ling Liu; A Sidney Barritt; Morris Weinberger; John E Paul; Bruce Fried; Justin G Trogdon
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

8.  Association Between Hepatocellular Carcinoma and Type 2 Diabetes Mellitus in Chinese Hepatitis B Virus Cirrhosis Patients: A Case-Control Study.

Authors:  Huixian Han; Han Deng; Tao Han; Haitao Zhao; Feifei Hou; Xingshun Qi
Journal:  Med Sci Monit       Date:  2017-07-09

9.  Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China.

Authors:  Xu Li; Hongqin Xu; Yang Gao; Meng Pan; Le Wang; Pujun Gao
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

10.  Type 2 diabetes mellitus increases liver transplant-free mortality in patients with cirrhosis: A systematic review and meta-analysis.

Authors:  Zi-Jin Liu; Yi-Jie Yan; Hong-Lei Weng; Hui-Guo Ding
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.